Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) CMO Rebecca Taub sold 27,845 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $245.14, for a total value of $6,825,923.30. Following the transaction, the chief marketing officer now directly owns 458,999 shares of the company’s […]
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research report report published on Thursday. Several other brokerages also recently commented on MDGL. UBS Group raised their target price on Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a buy rating in a research note on […]